Thermaiscan signed a Memorandum of Understanding (MoU) with AstraZeneca Singapore Thursday 25 of November.
The MoU – signed with 5 tech partners – aims to pilot data- and artificial intelligence-driven projects in Singapore, to propel and drive healthcare improvement.
The multi-party collaboration is facilitated by A.Catalyst Network, AstraZeneca’s global healthcare innovation network, and supports Singapore’s “3 Beyonds” strategy for a future-ready healthcare ecosystem.
The five tech partners collaborating with AstraZeneca Singapore are
– Hewlett Packard Enterprise
AstraZeneca’s A.Catalyst Network brings together partners across the public and private sectors to unlock the power of innovation and transform care delivery for improved patient experience and outcomes”, said Vinod Narayanan, Country President of AstraZeneca Singapore.Vinod Narayanan, Country President of AstraZeneca Singapore.
“Facilitating such partnerships will drive improvement in the healthcare ecosystem while providing patients with access to new digital healthcare solutions that can revolutionise the management of challenging diseases such as cancer, diabetes, heart failure and respiratory diseases.”
A huge thank you to all Thermaiscan supporters
We would like to take this opportunity to thank all our collaborators and partners, helping us pave the way forward and save lives with the use of technology.
Special thanks to Ignite Sweden, Business Sweden Asia-Pacific, Regeringskansliet, Embassy of Sweden, Singapore, AstraZeneca Singapore and the Singapore Ministry of Health.
About AstraZeneca Singapore
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca Singapore is one of Singapore’s leading biopharmaceutical companies that aim to make a difference in the healthcare industry by touching and saving as many lives as we can through our innovation in the scientific medical field.